Plus Therapeutics' REYOBIQ Phase 1 Data Shows Strong Survival Benefit in Leptomeningeal Metastases
PSTV has more than doubled off its 52-week low of $2.9 on light trading volume (0.3× avg).
Summary
Plus Therapeutics announced positive clinical and translational data from its Phase 1 ReSPECT-LM trial for REYOBIQ™ in leptomeningeal metastases (LM), presented at the AANS Annual Scientific Meeting. The data highlighted favorable safety, robust anti-tumor activity, and encouraging survival outcomes, with a median overall survival of approximately 9 months compared to historical survival of 2-6 months. This is a significant de-risking event for REYOBIQ, a key therapeutic candidate for a company that recently reported substantial doubt about its ability to continue as a going concern. The positive Phase 1 results, especially the survival benefit in an unmet medical need, could be a strong catalyst for the stock and potentially attract future funding or partnerships. Investors should monitor the progress of the ongoing multiple-dose trial.
At the time of this announcement, PSTV was trading at $6.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.8M. The 52-week trading range was $2.90 to $23.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.